Author

Luisa Bertin

USTEKINUMAB TREATMENT IN CROHN’S DISEASE AND ULCERATIVE COLITIS: A REAL-WORLD COMPARISON BETWEEN ITS EFFECTIVENESS AND SAFETY IN THIS TWO POPULATIONS
USTEKINUMAB TREATMENT IN CROHN’S DISEASE AND ULCERATIVE COLITIS: A REAL-WORLD COMPARISON BETWEEN ITS EFFECTIVENESS AND SAFETY IN THIS TWO POPULATIONS

Luisa Bertin  et al.

RISK FACTORS OF MALIGNANCIES IN INFLAMMATORY BOWEL DISEASE: A SINGLE CENTER EXPERIENCE
RISK FACTORS OF MALIGNANCIES IN INFLAMMATORY BOWEL DISEASE: A SINGLE CENTER EXPERIENCE

Luisa Bertin  et al.

ENTERIC INFECTIONS WORSEN POST DISCHARGE OUTCOMES IN PATIENTS HOSPITALIZED FOR INFLAMMATORY BOWEL DISEASE FLARE: A SINGLE CENTER STUDY.
ENTERIC INFECTIONS WORSEN POST DISCHARGE OUTCOMES IN PATIENTS HOSPITALIZED FOR INFLAMMATORY BOWEL DISEASE FLARE: A SINGLE CENTER STUDY.

Luisa Bertin  et al.

USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY
USTEKINUMAB IS SUPERIOR IN TREATMENT PERSISTENCE AND COLECTOMY-FREE SURVIVAL AMONG SEQUENTIAL BIOLOGICAL THERAPIES IN MODERATE-TO-SEVERE ULCERATIVE COLITIS REFRACTORY TO ANTI-TNF – PRELIMINARY DATA OF A RETROSPECTIVE, MULTICENTRE STUDY

Luisa Bertin  et al.

Item 1 - 4 / 4
1